Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 2Liver Neoplasms 1Hepatitis B 1Diarrhea 1Colorectal Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × PHY 906 × Gastrointestinal × Clear all
NCT04000737 2025-04-13

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Yiviva Inc.

Phase 2 Completed
62 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

NCT00076609 2007-03-28

Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma

PhytoCeutica

Phase 1/2 Completed
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00036517 2005-06-24

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

PhytoCeutica

Phase 1/2 Terminated
30 enrolled
Gastrointestinal

Diarrhea, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡